- Epzicom®(as a combination product containing Abacavir, Lamivudine)
- Trizivir®(as a combination product containing Abacavir, Lamivudine, Zidovudine)
Lamivudine, when used alone or in combination with other antiviral medications, can cause serious damage to the liver and a condition called lactic acidosis. If you experience any of the following symptoms, call your doctor immediately: nausea, loss of appetite, excessive tiredness, weakness, dark yellow or brown urine, unusual bleeding or bruising, flu-like symptoms, yellowing of the skin or eyes, and pain in the upper right part of your stomach. Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to lamivudine.
Epivir tablets and liquid (used to treat human immunodeficiency virus [HIV]) are not interchangeable with Epivir-HBV tablets and liquid (used to treat hepatitis B infection). Epivir contains a higher dose of lamivudine than Epivir-HBV. Treatment with Epivir-HBV in patients infected with HIV may cause the HIV virus to be less treatable with lamivudine and other medicines. If you have both HIV and hepatitis B, you should take only Epivir. If you are taking Epivir-HBV for hepatitis B infection, talk to your doctor about your risks for HIV infection.
WHY is this medicine prescribed?
Lamivudine (Epivir) is used along with other medications to treat human immunodeficiency virus (HIV) infection. Lamivudine (Epivir-HBV) is used to treat hepatitis B infection. Lamivudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV and hepatitis B in the blood. Although lamivudine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
HOW should this medicine be used?
Lamivudine comes as a tablet and liquid to take by mouth. Lamivudine (Epivir) is usually taken every 12 hours (twice a day). Lamivudine (Epivir-HBV) is usually taken once a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take lamivudine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Continue to take lamivudine even if you feel well. Do not stop taking lamivudine without talking to your doctor.
Are there OTHER USES for this medicine?
Lamivudine is also used sometimes in combination with zidovudine (Retrovir, AZT) to treat healthcare workers or other individuals exposed to HIV infection after accidental contact with HIV-contaminated blood, tissues, or other body fluids. Talk to your doctor about the possible risks of using this drug for your condition.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What SPECIAL PRECAUTIONS should I follow?
Before taking lamivudine,
- tell your doctor and pharmacist if you are allergic to lamivudine or any other drugs.
- tell your doctor and pharmacist what prescription and nonprescription medications you are taking, especially trimethoprim/sulfamethoxazole (Bactrim, Septra) and vitamins.
- tell your doctor if you have or have ever had hepatitis B, kidney disease, or pancreas disease (in children only).
- tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking lamivudine, call your doctor. You should not breast-feed while taking lamivudine.
What should I do IF I FORGET to take a dose?
Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
What SIDE EFFECTS can this medicine cause?
Lamivudine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- loss of appetite
- trouble sleeping
- stuffy nose
If you experience any of the following symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:
- stomach pain
- vomiting (in children)
- nausea (in children)
- muscle pain
- numbness, tingling, or burning in the fingers or toes
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online [at Web Site] or by phone [1-800-332-1088].
What should I know about STORAGE and DISPOSAL of this medication?
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom). The liquid does not need to be refrigerated; however, it should be stored in a cool place. Throw away any medication that is outdated or no longer needed. Talk to your pharmacist about the proper disposal of your medication.
What should I do in case of OVERDOSE?
In case of overdose, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.
What OTHER INFORMATION should I know?
Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
AHFS® Consumer Medication Information. © Copyright, The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: October 15, 2012.